Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of a Single Dose of mRNA COVID-19 Vaccine in Chinese Adults With Hybrid Immunity: a Multicentre, Open-label, Single-arm, Post-marketing Study

NCT07834073 is registered in ClinicalTrials.gov with Jiangsu Province Centers for Disease Control and Prevention as lead sponsor.

NCT NCT07834073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07834073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of a Single Dose of mRNA COVID-19 Vaccine in Chinese Adults With Hybrid Immunity: a Multicentre, Open-label, Single-arm, Post-marketing Study
Lead sponsor
Jiangsu Province Centers for Disease Control and Prevention
Phase
Phase 4
Overall status
Completed
Start date
May 23, 2023
Completion date
February 28, 2024
Enrollment
2,052 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection